instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | ACYCLOVIR, CASPOFUNGIN, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34716288 | 20,124,988 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weaning failure'. | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34716288 | 20,099,180 | 2021-10-30 |
What was the outcome of reaction 'Drug ineffective'? | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | Fatal | ReactionOutcome | CC BY-NC-ND | 34716288 | 20,142,430 | 2021-10-30 |
What was the outcome of reaction 'Herpes simplex meningoencephalitis'? | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | Fatal | ReactionOutcome | CC BY-NC-ND | 34716288 | 20,124,988 | 2021-10-30 |
What was the outcome of reaction 'Herpes simplex'? | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | Fatal | ReactionOutcome | CC BY-NC-ND | 34716288 | 20,066,688 | 2021-10-30 |
What was the outcome of reaction 'Meningoencephalitis herpetic'? | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | Fatal | ReactionOutcome | CC BY-NC-ND | 34716288 | 20,099,180 | 2021-10-30 |
What was the outcome of reaction 'Respiratory failure'? | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | Fatal | ReactionOutcome | CC BY-NC-ND | 34716288 | 20,091,504 | 2021-10-30 |
What was the outcome of reaction 'Weaning failure'? | Herpes Simplex Virus Meningoencephalitis Following Pulse-Dose Methylprednisolone: A Case Report and Literature Review.
BACKGROUND Several cases of herpes simplex virus type 1 meningoencephalitis (HSVE) have been reported in patients receiving steroids, but the exact contribution of steroids to the disorder remains uncl... | Fatal | ReactionOutcome | CC BY-NC-ND | 34716288 | 20,099,180 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exposure during pregnancy'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Kawasaki^s disease'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | HEPARIN SODIUM | DrugsGivenReaction | CC BY | 34717662 | 21,017,342 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Live birth'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,786,554 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myalgia'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Premature delivery'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vasculitis'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,179,510 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AMOXICILLIN, PREDNISONE | DrugsGivenReaction | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
What is the weight of the patient? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | 2.92 kg. | Weight | CC BY | 34717662 | 21,017,342 | 2021-10-30 |
What was the administration route of drug 'AMOXICILLIN'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Transplacental | DrugAdministrationRoute | CC BY | 34717662 | 20,169,057 | 2021-10-30 |
What was the dosage of drug 'AMOXICILLIN'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | AT 6 WEEKS GESTATION | DrugDosageText | CC BY | 34717662 | 20,195,492 | 2021-10-30 |
What was the outcome of reaction 'Diarrhoea'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
What was the outcome of reaction 'Kawasaki^s disease'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 21,017,342 | 2021-10-30 |
What was the outcome of reaction 'Live birth'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 20,786,554 | 2021-10-30 |
What was the outcome of reaction 'Maternal exposure during pregnancy'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 20,786,554 | 2021-10-30 |
What was the outcome of reaction 'Myalgia'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
What was the outcome of reaction 'Nausea'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
What was the outcome of reaction 'Steroid dependence'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 20,168,994 | 2021-10-30 |
What was the outcome of reaction 'Tachycardia foetal'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovering | ReactionOutcome | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
What was the outcome of reaction 'Vasculitis'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovering | ReactionOutcome | CC BY | 34717662 | 20,179,510 | 2021-10-30 |
What was the outcome of reaction 'Vomiting'? | A case report of a severe neonatal systemic vasculitis on the first day of life.
BACKGROUND
Neonatal systemic vasculitis syndromes have been reported in infants born to mothers with systemic lupus erythematosus, Sjögren's syndrome, Behҫet's disease, cutaneous polyarteritis nodosa and anti-neutrophil cytoplasmic antibod... | Recovered | ReactionOutcome | CC BY | 34717662 | 20,179,098 | 2021-10-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal pain'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC | 34720823 | 19,718,438 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaphylactic reaction'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC | 34720823 | 19,718,438 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anxiety'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC | 34720823 | 19,718,438 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug hypersensitivity'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE | DrugsGivenReaction | CC BY-NC | 34720823 | 19,739,149 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug level abnormal'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC | 34720823 | 19,718,438 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC | 34720823 | 19,718,438 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE | DrugsGivenReaction | CC BY-NC | 34720823 | 20,071,378 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy change'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE | DrugsGivenReaction | CC BY-NC | 34720823 | 20,071,378 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Throat irritation'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC | 34720823 | 19,718,438 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Type I hypersensitivity'. | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | FOLIC ACID, INFLIXIMAB, METHOTREXATE, OMEPRAZOLE, PREDNISONE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the dosage of drug 'FOLIC ACID'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | UNKNOWN | DrugDosageText | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the dosage of drug 'METHOTREXATE'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | UNKNOWN | DrugDosageText | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the dosage of drug 'OMEPRAZOLE'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | UNKNOWN | DrugDosageText | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the outcome of reaction 'Abdominal pain'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | Recovered | ReactionOutcome | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the outcome of reaction 'Anaphylactic reaction'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | Recovered | ReactionOutcome | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the outcome of reaction 'Drug specific antibody present'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | Recovered | ReactionOutcome | CC BY-NC | 34720823 | 19,739,149 | 2021 |
What was the outcome of reaction 'Dyspnoea'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | Recovered | ReactionOutcome | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the outcome of reaction 'Hypersensitivity'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | Recovered | ReactionOutcome | CC BY-NC | 34720823 | 19,718,438 | 2021 |
What was the outcome of reaction 'Throat irritation'? | Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease.
Ustekinumab is a monoclonal antibody used as treatment for various inflammatory conditions. We present a pediatric patient with Crohn's disease who did not tolerate infliximab and was then changed to ustekinumab. He developed anaphylaxis ... | Recovered | ReactionOutcome | CC BY-NC | 34720823 | 19,718,438 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemoglobin decreased'. | Apixaban Causing Hepatic Cystic Bleeding: A Rare but a Life-Threatening Complication.
Cystic lesions of the liver are a heterogeneous group of disorders with varied etiology, prevalence, and clinical manifestations. Fibropolycystic liver disease encompasses a spectrum of related liver and biliary tract lesions caused b... | APIXABAN | DrugsGivenReaction | CC BY-NC | 34720842 | 20,049,746 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhagic hepatic cyst'. | Apixaban Causing Hepatic Cystic Bleeding: A Rare but a Life-Threatening Complication.
Cystic lesions of the liver are a heterogeneous group of disorders with varied etiology, prevalence, and clinical manifestations. Fibropolycystic liver disease encompasses a spectrum of related liver and biliary tract lesions caused b... | APIXABAN | DrugsGivenReaction | CC BY-NC | 34720842 | 20,089,318 | 2021 |
What was the administration route of drug 'APIXABAN'? | Apixaban Causing Hepatic Cystic Bleeding: A Rare but a Life-Threatening Complication.
Cystic lesions of the liver are a heterogeneous group of disorders with varied etiology, prevalence, and clinical manifestations. Fibropolycystic liver disease encompasses a spectrum of related liver and biliary tract lesions caused b... | Oral | DrugAdministrationRoute | CC BY-NC | 34720842 | 20,089,318 | 2021 |
What was the outcome of reaction 'Haemorrhagic hepatic cyst'? | Apixaban Causing Hepatic Cystic Bleeding: A Rare but a Life-Threatening Complication.
Cystic lesions of the liver are a heterogeneous group of disorders with varied etiology, prevalence, and clinical manifestations. Fibropolycystic liver disease encompasses a spectrum of related liver and biliary tract lesions caused b... | Recovered | ReactionOutcome | CC BY-NC | 34720842 | 20,089,318 | 2021 |
What was the outcome of reaction 'Erythema multiforme'? | First Report of Erythema Multiforme Minor Caused by Raloxifene Hydrochloride.
Raloxifene is a drug used in postmenopausal women with osteoporosis. Although hot flashes are known side effects of raloxifene, to the best of our knowledge, erythema multiforme (EM) minor has not been previously reported. Herein, we report a... | Recovered | ReactionOutcome | CC BY-NC | 34720916 | 20,084,344 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Palliative Radiotherapy Provided Good Pain Relief for Painful Adrenal Metastasis.
Adrenal metastases often occur in patients with metastasized lung cancer, but symptoms rarely develop. A 45-year-old man presented with right abdominal pain requiring strong opioids due to large right adrenal metastasis of lung adenocarci... | ACETAMINOPHEN\TRAMADOL, CARBOPLATIN, GIMERACIL\OTERACIL\TEGAFUR, NAPROXEN, OXYCODONE HYDROCHLORIDE, PEMBROLIZUMAB, PEMETREXED | DrugsGivenReaction | CC BY-NC | 34720926 | 20,637,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Palliative Radiotherapy Provided Good Pain Relief for Painful Adrenal Metastasis.
Adrenal metastases often occur in patients with metastasized lung cancer, but symptoms rarely develop. A 45-year-old man presented with right abdominal pain requiring strong opioids due to large right adrenal metastasis of lung adenocarci... | CARBOPLATIN, GIMERACIL\OTERACIL\TEGAFUR, PEMBROLIZUMAB, PEMETREXED | DrugsGivenReaction | CC BY-NC | 34720926 | 20,651,451 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to adrenals'. | Palliative Radiotherapy Provided Good Pain Relief for Painful Adrenal Metastasis.
Adrenal metastases often occur in patients with metastasized lung cancer, but symptoms rarely develop. A 45-year-old man presented with right abdominal pain requiring strong opioids due to large right adrenal metastasis of lung adenocarci... | CARBOPLATIN, GIMERACIL\OTERACIL\TEGAFUR, PEMBROLIZUMAB, PEMETREXED | DrugsGivenReaction | CC BY-NC | 34720926 | 20,651,451 | 2021 |
What was the dosage of drug 'GIMERACIL\OTERACIL\TEGAFUR'? | Palliative Radiotherapy Provided Good Pain Relief for Painful Adrenal Metastasis.
Adrenal metastases often occur in patients with metastasized lung cancer, but symptoms rarely develop. A 45-year-old man presented with right abdominal pain requiring strong opioids due to large right adrenal metastasis of lung adenocarci... | 100 MILLIGRAM, DAILY | DrugDosageText | CC BY-NC | 34720926 | 20,651,451 | 2021 |
What was the dosage of drug 'NAPROXEN'? | Palliative Radiotherapy Provided Good Pain Relief for Painful Adrenal Metastasis.
Adrenal metastases often occur in patients with metastasized lung cancer, but symptoms rarely develop. A 45-year-old man presented with right abdominal pain requiring strong opioids due to large right adrenal metastasis of lung adenocarci... | 100 MILLIGRAM, 100 MG 3 TIMES PER DAY | DrugDosageText | CC BY-NC | 34720926 | 20,637,980 | 2021 |
What was the dosage of drug 'PEMETREXED'? | Palliative Radiotherapy Provided Good Pain Relief for Painful Adrenal Metastasis.
Adrenal metastases often occur in patients with metastasized lung cancer, but symptoms rarely develop. A 45-year-old man presented with right abdominal pain requiring strong opioids due to large right adrenal metastasis of lung adenocarci... | 500 MILLIGRAM/SQ. METER, UNK | DrugDosageText | CC BY-NC | 34720926 | 20,651,451 | 2021 |
What was the outcome of reaction 'Metastases to adrenals'? | Palliative Radiotherapy Provided Good Pain Relief for Painful Adrenal Metastasis.
Adrenal metastases often occur in patients with metastasized lung cancer, but symptoms rarely develop. A 45-year-old man presented with right abdominal pain requiring strong opioids due to large right adrenal metastasis of lung adenocarci... | Recovering | ReactionOutcome | CC BY-NC | 34720926 | 20,651,451 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alanine aminotransferase increased'. | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOCETAXEL, EPIRUBICIN, ETHYL LOFLAZEPATE, METOCLOPRAMIDE, PEGFILGRASTIM, PERTUZUMAB, ROSUVASTATIN, SITAGLIPTIN PHOSPHATE, TRASTUZUMAB, TRIHEXYPHENIDYL HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC | 34720928 | 20,087,698 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aspartate aminotransferase increased'. | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOCETAXEL, EPIRUBICIN, ETHYL LOFLAZEPATE, METOCLOPRAMIDE, PEGFILGRASTIM, PERTUZUMAB, ROSUVASTATIN, SITAGLIPTIN PHOSPHATE, TRASTUZUMAB, TRIHEXYPHENIDYL HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC | 34720928 | 20,087,698 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gamma-glutamyltransferase increased'. | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOCETAXEL, EPIRUBICIN, ETHYL LOFLAZEPATE, METOCLOPRAMIDE, PEGFILGRASTIM, PERTUZUMAB, ROSUVASTATIN, SITAGLIPTIN PHOSPHATE, TRASTUZUMAB, TRIHEXYPHENIDYL HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC | 34720928 | 20,087,698 | 2021 |
What was the administration route of drug 'PEGFILGRASTIM'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34720928 | 20,087,698 | 2021 |
What was the dosage of drug 'ARIPIPRAZOLE'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | 6 MILLIGRAM, 2X/DAY | DrugDosageText | CC BY-NC | 34720928 | 19,940,599 | 2021 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | EVERY 3 WEEKS, 4 TIMES | DrugDosageText | CC BY-NC | 34720928 | 20,087,698 | 2021 |
What was the dosage of drug 'EPIRUBICIN'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | EVERY 3 WEEKS, 4 TIMES | DrugDosageText | CC BY-NC | 34720928 | 20,087,698 | 2021 |
What was the dosage of drug 'LOPERAMIDE'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | UNK (1 MG PER REQUEST) | DrugDosageText | CC BY-NC | 34720928 | 19,971,941 | 2021 |
What was the dosage of drug 'ROSUVASTATIN'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | 5 MILLIGRAM, QD | DrugDosageText | CC BY-NC | 34720928 | 20,087,698 | 2021 |
What was the dosage of drug 'SITAGLIPTIN PHOSPHATE'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | 50 MILLIGRAM, QD | DrugDosageText | CC BY-NC | 34720928 | 20,087,698 | 2021 |
What was the outcome of reaction 'Diarrhoea'? | Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.
Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postme... | Recovering | ReactionOutcome | CC BY-NC | 34720928 | 20,087,698 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tumour lysis syndrome'. | Tumor Lysis Syndrome in a Low-Risk Pancreatic Cancer Patient.
Tumor lysis syndrome (TLS) is the most common hematologic emergency encountered during the treatment of high-grade malignancies. While it can lead to death, the prognosis is typically excellent if caught early on in the course. Risk stratification prior to t... | GEMCITABINE, PACLITAXEL | DrugsGivenReaction | CC BY-NC | 34720933 | 20,515,784 | 2021 |
What was the dosage of drug 'PACLITAXEL'? | Tumor Lysis Syndrome in a Low-Risk Pancreatic Cancer Patient.
Tumor lysis syndrome (TLS) is the most common hematologic emergency encountered during the treatment of high-grade malignancies. While it can lead to death, the prognosis is typically excellent if caught early on in the course. Risk stratification prior to t... | PACLITAXEL [NAB-PACLITAXEL] (PALLIATIVE CHEMOTHERAPY) | DrugDosageText | CC BY-NC | 34720933 | 20,501,860 | 2021 |
What was the outcome of reaction 'Tumour lysis syndrome'? | Tumor Lysis Syndrome in a Low-Risk Pancreatic Cancer Patient.
Tumor lysis syndrome (TLS) is the most common hematologic emergency encountered during the treatment of high-grade malignancies. While it can lead to death, the prognosis is typically excellent if caught early on in the course. Risk stratification prior to t... | Fatal | ReactionOutcome | CC BY-NC | 34720933 | 20,515,784 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, FILGRASTIM, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 34720934 | 20,533,386 | 2021 |
What was the administration route of drug 'FILGRASTIM'? | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34720934 | 20,533,386 | 2021 |
What was the administration route of drug 'LEVOFLOXACIN'? | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | Oral | DrugAdministrationRoute | CC BY-NC | 34720934 | 20,516,535 | 2021 |
What was the administration route of drug 'PIPERACILLIN SODIUM\TAZOBACTAM SODIUM'? | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34720934 | 20,516,535 | 2021 |
What was the dosage of drug 'DOXORUBICIN'? | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | R-CHOP REGIMEN; ON DAY 2 EVERY 3 WEEKS | DrugDosageText | CC BY-NC | 34720934 | 20,576,514 | 2021 |
What was the dosage of drug 'PEGFILGRASTIM'? | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | 3.6 MILLIGRAM, ON DAY 4, 2ND CYCLE | DrugDosageText | CC BY-NC | 34720934 | 20,516,535 | 2021 |
What was the outcome of reaction 'Disease recurrence'? | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | Recovered | ReactionOutcome | CC BY-NC | 34720934 | 20,533,386 | 2021 |
What was the outcome of reaction 'Helicobacter infection'? | Recurrent Fever due to Helicobacter cinaedi Infection during R-CHOP Chemotherapy in Diffuse Large B-Cell Lymphoma: Case Report and Literature Review.
Fever due to Helicobacter cinaedi bacteremia under chemotherapy has not been widely recognized among clinicians. We experienced a 72-year-old man with diffuse large B-cel... | Recovered | ReactionOutcome | CC BY-NC | 34720934 | 20,576,514 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ascites'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aspiration pleural cavity'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chest tube insertion'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pericardial effusion'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleural effusion'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleurodesis'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy cessation'. | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | ALECTINIB HYDROCHLORIDE, BRIGATINIB, FUROSEMIDE, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the administration route of drug 'ALECTINIB HYDROCHLORIDE'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Oral | DrugAdministrationRoute | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the outcome of reaction 'Aspiration pleural cavity'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Recovering | ReactionOutcome | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the outcome of reaction 'Cardiac failure'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Recovering | ReactionOutcome | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the outcome of reaction 'Chest tube insertion'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Recovering | ReactionOutcome | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the outcome of reaction 'Dyspnoea'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Recovering | ReactionOutcome | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the outcome of reaction 'Pericardial effusion'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Recovered | ReactionOutcome | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the outcome of reaction 'Pleural effusion'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Recovered | ReactionOutcome | CC BY-NC | 34720935 | 20,700,796 | 2021 |
What was the outcome of reaction 'Pleurodesis'? | Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effu... | Recovering | ReactionOutcome | CC BY-NC | 34720935 | 20,700,796 | 2021 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.